1 / 8

Hereditary Angioedema Treatment Market by Drug Class, Geography and Forecast to 2027

Hereditary angioedema (HAE) is a rare and potentially life-threatening autosomal disease, characterized by swelling in the hands, feet, face, abdomen, upper airways, and other body parts. It occurs in 1 in 10,000 to 1 in 50,000 people.<br>

MarketTrends
Télécharger la présentation

Hereditary Angioedema Treatment Market by Drug Class, Geography and Forecast to 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hereditary Angioedema Treatment Market Hereditary Angioedema Treatment Market Segmentation by Drug Class: C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, and Others; Route of Administration: Intravenous, Subcutaneous Injection, and Oral; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others, Forecast, 2019 - 2027 ©2019 Transparency Market Research, All Rights Reserved

  2. Table of Content ©2019 Transparency Market Research, All Rights Reserved

  3. Hereditary Angioedema Treatment Market - Snapshot Transparency Market Research has published a new report on the hereditary angioedema treatment market for the forecast period of 2019–2027. According to the report, the global hereditary angioedema treatment market is projected to expand at a CAGR of ~9% from 2019 to 2027. Hereditary angioedema is an autosomal disorder, wherein, the level of functional C1 esterase inhibitor protein is low. This leads to increased concentration of bradykinin. ©2019 Transparency Market Research, All Rights Reserved

  4. Report Highlights Growth of the global hereditary angioedema treatment market can be attributed to rise in the prevalence of hereditary angioedema and increase in awareness about HAE across the globe. Government organizations and other agencies are creating public awareness through various campaigns regarding the diagnosis, treatment, and care of hereditary angioedema. The U.S. Hereditary Angioedema Association (U.S. HAEA) organized a fundraising event and other campaigns in September 2017 to create awareness about the disorder within the community. Request For Sample ©2019 Transparency Market Research, All Rights Reserved

  5. Continue.. Shire plc (Takeda Pharmaceutical Company Limited), CSL Limited, and Pharming Group NV are leading players in the global hereditary angioedema treatment market. The global hereditary angioedema treatment market is projected to be driven by novel therapies and pipeline products during the forecast period. Ionis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals Ltd., and Attune Pharmaceuticals have several different products in the pipeline for the treatment of HAE. Request For Brochure ©2019 Transparency Market Research, All Rights Reserved

  6. Contact To know more about us, please visit our website: www.transparencymarketresearch.com For sales queries or new topics email us on: sales@transparencymarketresearch.com Thank You ©2019 Transparency Market Research, All Rights Reserved

More Related